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Corticosteroids are the only proven treatment for giant cell arteritis. This study shows upregulated angiotensin II type 1 receptors in both smooth muscle cells and inflammatory cells in the temporal arteries from patients with GCA.
Introduction
Giant cell arteritis (GCA) is a granulomatous form of vasculitis involving large and mediumsized vessels. 1 The extracranial branches of the aorta are the main targets, and the major source of diagnostic biopsies is the temporal artery. The clinical manifestations of GCA are due to end organ ischemia and include blindness, jaw claudication, headaches, stroke and aortic arch syndrome. These symptoms are often accompanied by signs of systemic inflammation, such as malaise, anorexia, fever and myalgia. Excessive amounts of acute phase proteins are produced and the erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and interleukin-6 levels are elevated.
GCA is a form of panarteritis with transmural inflammation, involving the media, intima and adventitia of the affected arteries. Active disease is characterized by a nodular granulomatous reaction that is centered around a fragmented internal elastic lamina with inflammatory cells in the intima or media. 2, 3 The typical lesions are formed by interferon-γ-producing CD4 + T cells and macrophages. 3, 4 Thrombosis may be present, although ischemic symptoms are usually the result of lumen narrowing resulting from mural thickening.
Currently, giant cell arteritis (GCA) is primarily treated with corticosteroids or immunomodulating agents. 5 However, there is interest in identifying other non-corticosteroid alternatives because of the numerous complications associated with long-term corticosteroid treatment. 6 The complications appear to be dose related, and non-corticosteroid medication may therefore be beneficial. Studies have been carried out on methotrexate, anti-TNF-a agents, and others, such as azathioprine and cyclophosphamide, 7 but none of these has yet been recommended for GCA. Modulating the inflammatory response by inhibiting the reninangiotensin system may be an alternative approach for the treatment of GCA.
Angiotensin II receptor inhibitors are effective in preventing atherosclerosis. GCA and atherosclerosis have similar injury pathways, both of which involve vessel inflammation.
Angiotensin II is a vasoactive peptide that is known to play a role in vessel inflammation in atherosclerosis. Angiotensin II modulates the immune response via the production of NF-κB in the cytoplasm of mature phagocytes, resulting in the transcription of inflammatory cytokines and chemokines, including IL-1beta, IL-6, IFN-gamma and TNF-alpha, and IL-8, MCP-1 and CAM-1, respectively. [8] [9] [10] Angiotensin-converting enzyme inhibitors reduce the expression of monocyte chemo-attractant protein-1 and concomitant macrophage plaque infiltration in animal models of atherosclerosis. 11 In patients with carotid artery disease, the angiotensin receptor blocker irbersartan inhibits metalloproteinase activity, as well as T-cell and macrophage infiltration in the vascular wall.
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To our knowledge, no study has yet been performed to elucidate the possible role of angiotensin II receptors in GCA in humans. In the present study, angiotensin type 1 (AT 1 ) and type 2 (AT 2 ) receptor expression was investigated in temporal arteries, using immunohistochemistry. The immunostaining intensity in temporal arteries from patients with GCA was compared to that in arteries from control patients. The latter were clinically suspected of having GCA, but this diagnosis was ruled out.
MATERIALS AND METHODS

Tissue collection
Temporal artery vessel biopsy specimens from 20 patients were retrieved from the Department of Pathology, Lund University, Sweden, where they had been routinely examined for histopathology. All patients' symptoms and background characteristics are listed in Table   1 . The original pathology reports were reviewed to verify the diagnosis GCA. The diagnosis was based on the American College of Rheumatology 1990 criteria for the classification of GCA 13 . The absence of inflammatory lesions in a sample led to the categorization of the sample as negative. Temporal arteries from ten patients with GCA were compared to arteries from ten patients who were clinically suspected of having GCA, but the diagnosis had been ruled out (control patients). The histopathological findings in the temporal arteries from all 20 patients are listed in Table 2 .
Ethics
The samples were handled in accordance with permission obtained from the Lund University Human Ethics Committee (LU 818-01), and the study conformed to the principles outlined in the Declaration of Helsinki.
Immunohistochemistry
Four-μm sections were cut from formalin-fixed, paraffin-embedded blocks and dried at 60 °C for one hour. After dewaxing and rehydration, the sections were treated with 10 mM citrate buffer, pH 6.0, in a microwave oven for 15 min for antigen retrieval. Immunohistochemical staining with rabbit polyclonal antibody AT 1 receptor (sc-1173) and AT 2 receptor (sc-9034, both from Santa Cruz Biotechnology, Inc., Santa Cruz, CA) diluted 1:50, anti CD68 (Dako diluted 1:500 (Dako M0851) and CD31 diluted 1:50 (Dako M823) was performed in an automated immunostainer, TechMate 500 (Ventana Biotek, Tuscan, AZ, USA), using the biotin-streptavidin-peroxidase method with diaminobenzidine as the chromogen (Dako REAL™ Detection System, Peroxidase/DAB+, Rabbit/Mouse). Mayer's hematoxylin was used for counterstaining. Primary antibodies were omitted for negative control. Details and antibody specificity are given on the company's homepage. The samples were examined with a microscope (Olympus BX60, Tokyo, Japan) and photographed using a digital camera (Pixera Pro 600ES, Los Gatos, CA, USA).
Calculations and statistics
Calculations were performed on the results obtained from temporal arteries from 10 patients with GCA and 10 control patients. The immunofluorescence intensity was measured using 
Results
Hematoxylin-eosin staining
Hematoxylin-eosin-stained sections of temporal arteries from patients with GCA showed intimal hyperplasia with reduction of the lumen, internal elastic lamina degeneration and band-shaped infiltrates of inflammatory cells, including lymphocytes, histocytes, and multinucleated giant cells (Table 2 and Figure 1 ). Immunostaining for CD68 demonstrated strong labeling in the area of inflammatory cell infiltrates. Immunostaining for CD45 was also seen, but was not as prominent. In the more severe cases of GCA, transmural inflammatory infiltrates and necrosis were seen in portions of the vascular wall. The control patients were clinically suspected cases of GCA, in which the diagnosis of GCA had been ruled out. The temporal arteries from these control patients had intimal hyperplasia and sub-intimal fibrosis and focal loss of internal elastic lamina, suggestive of atherosclerotic disease.
AT 1 receptor immunostaining
Immunostaining for AT 1 
Discussion
Major findings
The objective of this study was to investigate the possible roles of AT 1 and AT 2 receptors in GCA. Temporal arteries from patients diagnosed with GCA were compared to those from control patients that were clinically suspected cases but the diagnosis of giant cell arteritis had been ruled out. The major finding of the present study was increased immunostaining intensities for AT 1 receptors in both smooth muscle cells and inflammatory cells in the temporal arteries from patients with GCA.
GCA diagnosis
The patients included in the present study were diagnosed as having GCA according to the American College of Rheumatology 1990 criteria for the classification of giant cell arteritis, which have a sensitivity of 94% and a specificity of 91%. 13 The criteria were initially developed as a research tool, and the presence of three or more of the following criteria are required for the diagnosis of GCA: age of onset greater than 50 years, onset of new headache, temporal artery abnormality (tender or reduced pulsation), elevated ESR, defined as 50 mm/h, and abnormal arterial biopsy. Table 1 gives the characteristics of the patients' clinical presentation.
Hematoxylin-eosin-stained sections of temporal arteries demonstrated features that are typical of giant cell arteritis, 14 including intimal hyperplasia with reduction of the lumen, internal elastic lamina degeneration and band-shaped infiltrates of inflammatory cells, including lymphocytes, histocytes, and multinucleated giant cells. In the more severe cases of GCA, transmural inflammatory infiltrates and necrosis were seen in parts of the vascular wall. Table   2 provides a detailed presentation of the vascular wall lesions in study patients with GCA.
Angiotensin II receptors in the vascular wall
Two angiotensin II receptors have been identified and cloned in man: the AT 1 and AT 2 receptors. 15, 16 AT 1 and AT 2 receptors are distributed heterogeneously in human tissues and blood vessels. 17 In the present study, immunostaining for AT 1 receptors was seen on the smooth muscle cells of the media in the temporal arteries from the control patients. Only faint immunostaining was seen for AT 2 receptors, primarily in the endothelial cell layer, and to a lesser extent in the smooth muscle cell layer. This is in accordance with previous findings of AT 1 receptors on smooth muscle cells, and AT 2 receptors on endothelial cells.
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Immunostaining for AT 2 on the smooth muscle cells of arteries has also been reported. 22 In the present study, the levels of AT 1 receptors on smooth muscle cells were higher in the temporal arteries from the patients with GCA than in the temporal arteries from the control patients. Angiotensin II is a potent vasoconstrictor and mitogen of vascular smooth muscle cells. The stimulation of AT 1 receptors is known to result in progression of atherosclerotic lesions, inflammation and plaque rupture. 23, 24 The upregulation of AT 1 receptors in GCA could make the arteries prone to tonic contraction and spasm, resulting in the progression of vascular wall inflammation.
Angiotensin II receptors and vascular wall inflammation
High AT 1 receptor immunostaining intensity in arteries from patients with GCA was not only due to increased protein expression on the smooth muscle cells, but also to high levels of AT 1 receptor expression on inflammatory cells, including lymphocytes and macrophages infiltrating the vascular lesions. AT 1 receptors have previously been demonstrated on both lymphocytes and macrophages. [25] [26] [27] Angiotensin II affects human T-lymphocyte function via AT 1 receptor activation, which results in increased production of pro-inflammatory cytokines such as interferon-γ and TNF-α. 28 29 The intense expression of the AT 1 receptor in inflammatory cells in the GCA vascular lesion may contribute to the progression of the disease. We suggest that inhibiting the angiotensin system may offer a new means of pharmacologically modulating the progression of GCA. Indeed, inhibitors of AT 1 receptors have been shown to modify the progression of atherosclerosis and stabilize atheromatous plaques. 11, 12 Atherosclerosis and GCA are both vascular diseases in which inflammation is a common entity.
Conclusions
The present study demonstrates high levels of AT 1 receptor expression in both the vascular smooth muscle cells and inflammatory cells in the temporal arteries of patients with GCA.
Increased activity in the angiotensin II system may play a role in the progression of inflammation in GCA. We suggest that inhibition of the renin-angiotensin system may provide a non-corticosteroid alternative for the treatment of GCA inflammation. Table 2 Giant cell arteritis (GCA) was defined using The American College of Rheumatology (1990) criteria for the classification of giant cell arteritis. 13 The 
